Eidos Therapeutics Inc
(EIDX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 131,400 | 147,064 | 157,147 | 166,568 | 176,689 |
| Receivables | 197 | 72 | 34 | 29 | 21 |
| TOTAL | $135,525 | $149,296 | $158,970 | $169,845 | $178,955 |
| Non-Current Assets | |||||
| PPE Net | 204 | 196 | 209 | 218 | 219 |
| Other Non-Current Assets | 3,552 | 3,705 | 933 | 163 | 169 |
| TOTAL | $3,756 | $3,901 | $1,142 | $381 | $388 |
| Total Assets | $139,281 | $153,197 | $160,112 | $170,226 | $179,343 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,186 | 3,619 | 2,212 | 2,623 | 2,665 |
| Accrued Expenses | 4,027 | 3,953 | 2,577 | 3,427 | 2,631 |
| TOTAL | $6,489 | $7,841 | $4,789 | $6,050 | $5,296 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 946 | 1,055 | 316 | 357 | 403 |
| TOTAL | $946 | $1,055 | $316 | $357 | $403 |
| Total Liabilities | $7,435 | $8,896 | $5,105 | $6,407 | $5,699 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 36,884 | 36,828 | 36,819 | 36,747 | 36,752 |
| Common Shares | 37 | 37 | 37 | 37 | 37 |
| Retained earnings | -91,056 | -77,003 | -65,270 | -50,908 | -40,732 |
| TOTAL | $131,846 | $144,301 | $155,007 | $163,819 | $173,644 |
| Total Liabilities And Equity | $139,281 | $153,197 | $160,112 | $170,226 | $179,343 |